Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANCN NASDAQ:CERC NASDAQ:CTXR NASDAQ:MNOV NASDAQ:MREO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANCNAnchiano Therapeutics$2.82-7.0%$21.77$0.51▼$10.55$20.92M0.933.15 million shs140,517 shsCERCCerecor$10.14-4.8%$2.60$1.98▼$4.50$973.53M1.441.27 million shs187,458 shsCTXRCitius Pharmaceuticals$1.17+2.6%$1.37$0.65▼$15.25$19.90M1.351.12 million shs181,776 shsMNOVMediciNova$1.25+0.8%$1.30$1.13▼$2.55N/A0.4326,276 shs18,306 shsMREOMereo BioPharma Group$1.76$1.76$1.47▼$4.72$279.84M0.471.67 million shs574,041 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANCNAnchiano Therapeutics0.00%-1.86%+226.06%+146.54%+69.88%CERCCerecor0.00%-8.15%+18.13%+131.13%+18.65%CTXRCitius Pharmaceuticals-5.79%-6.56%-14.29%+33.60%-91.23%MNOVMediciNova+0.81%-1.59%-5.34%-1.59%-31.87%MREOMereo BioPharma Group-4.86%-1.68%+1.15%-37.14%-58.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANCNAnchiano Therapeutics$2.82-7.0%$21.77$0.51▼$10.55$20.92M0.933.15 million shs140,517 shsCERCCerecor$10.14-4.8%$2.60$1.98▼$4.50$973.53M1.441.27 million shs187,458 shsCTXRCitius Pharmaceuticals$1.17+2.6%$1.37$0.65▼$15.25$19.90M1.351.12 million shs181,776 shsMNOVMediciNova$1.25+0.8%$1.30$1.13▼$2.55N/A0.4326,276 shs18,306 shsMREOMereo BioPharma Group$1.76$1.76$1.47▼$4.72$279.84M0.471.67 million shs574,041 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANCNAnchiano Therapeutics0.00%-1.86%+226.06%+146.54%+69.88%CERCCerecor0.00%-8.15%+18.13%+131.13%+18.65%CTXRCitius Pharmaceuticals-5.79%-6.56%-14.29%+33.60%-91.23%MNOVMediciNova+0.81%-1.59%-5.34%-1.59%-31.87%MREOMereo BioPharma Group-4.86%-1.68%+1.15%-37.14%-58.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANCNAnchiano Therapeutics 0.00N/AN/AN/ACERCCerecor 0.00N/AN/AN/ACTXRCitius Pharmaceuticals 2.50Moderate Buy$53.004,429.91% UpsideMNOVMediciNova 3.00Buy$7.00460.00% UpsideMREOMereo BioPharma Group 3.20Buy$7.40320.45% UpsideCurrent Analyst Ratings BreakdownLatest ANCN, CERC, MREO, CTXR, and MNOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025MNOVMediciNovaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/27/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/25/2025MREOMereo BioPharma GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $8.008/13/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.007/24/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.007/10/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$7.00 ➝ $5.006/30/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.006/16/2025MNOVMediciNovaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANCNAnchiano TherapeuticsN/AN/AN/AN/A$2.01 per shareN/ACERCCerecor$6.70M145.30N/AN/A$0.22 per share46.09CTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/AMNOVMediciNova$1MN/AN/AN/A$1.07 per shareN/AMREOMereo BioPharma Group$500K559.68N/AN/A$0.39 per share4.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANCNAnchiano Therapeutics-$27.12M-$3.4618.80N/AN/AN/A36.08%27.40%N/ACERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/ACTXRCitius Pharmaceuticals-$39.14MN/A0.000.94N/AN/A-60.03%-33.83%N/AMNOVMediciNova-$11.04M-$0.25N/AN/AN/AN/A-23.12%-21.85%11/12/2025 (Estimated)MREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-80.00%-66.94%11/11/2025 (Estimated)Latest ANCN, CERC, MREO, CTXR, and MNOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MNOVMediciNova-$0.07-$0.07N/A-$0.07N/A$0.14 million8/12/2025Q3 2025CTXRCitius Pharmaceuticals-$0.76-$0.80-$0.04-$0.80$1.92 million$1.92 million8/12/2025Q2 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$7.80 million$0.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANCNAnchiano TherapeuticsN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANCNAnchiano TherapeuticsN/A3.253.25CERCCerecor0.792.192.18CTXRCitius PharmaceuticalsN/A0.470.14MNOVMediciNovaN/A13.2613.26MREOMereo BioPharma GroupN/A8.138.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANCNAnchiano Therapeutics9.05%CERCCerecor62.84%CTXRCitius Pharmaceuticals16.88%MNOVMediciNova9.90%MREOMereo BioPharma Group62.83%Insider OwnershipCompanyInsider OwnershipANCNAnchiano Therapeutics6.88%CERCCerecor45.70%CTXRCitius Pharmaceuticals10.70%MNOVMediciNova13.60%MREOMereo BioPharma Group5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANCNAnchiano Therapeutics167.42 millionN/ANot OptionableCERCCerecor3196.01 millionN/ANot OptionableCTXRCitius Pharmaceuticals2017.01 million15.19 millionOptionableMNOVMediciNova10N/AN/AOptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionableANCN, CERC, MREO, CTXR, and MNOV HeadlinesRecent News About These CompaniesMereo BioPharma Group plc - Sponsored ADR $MREO Shares Sold by Adage Capital Partners GP L.L.C.September 9, 2025 | marketbeat.comMereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of "Buy" by BrokeragesSeptember 8, 2025 | marketbeat.comMereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of "Buy" by AnalystsSeptember 7, 2025 | americanbankingnews.comFrazier Life Sciences Management L.P. Buys 2,722,084 Shares of Mereo BioPharma Group plc - Sponsored ADR $MREOSeptember 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOSeptember 3, 2025 | prnewswire.comMereo BioPharma Group plc - Sponsored ADR $MREO Shares Sold by Tema Etfs LLCAugust 30, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 29, 2025 | globenewswire.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Mereo BioPharma Group (NASDAQ:MREO) StockAugust 27, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 27, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 25, 2025 | globenewswire.comAberdeen Group plc Acquires New Holdings in Mereo BioPharma Group plc - Sponsored ADR $MREOAugust 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 21, 2025 | globenewswire.comCantor Fitzgerald Has Positive View of MREO FY2026 EarningsAugust 17, 2025 | marketbeat.comQ3 EPS Forecast for Mereo BioPharma Group Reduced by AnalystAugust 17, 2025 | marketbeat.comTejara Capital Ltd Purchases 204,239 Shares of Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO)August 17, 2025 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Upgraded at Wall Street ZenAugust 17, 2025 | marketbeat.comAnalysts Offer Predictions for MREO Q1 EarningsAugust 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 16, 2025 | prnewswire.comAnalysts Set Expectations for MREO Q3 EarningsAugust 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANCN, CERC, MREO, CTXR, and MNOV Company DescriptionsAnchiano Therapeutics NASDAQ:ANCNAnchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.Cerecor NASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Citius Pharmaceuticals NASDAQ:CTXR$1.17 +0.03 (+2.63%) Closing price 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.85%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.MediciNova NASDAQ:MNOV$1.25 +0.01 (+0.81%) Closing price 04:00 PM EasternExtended Trading$1.25 0.00 (-0.32%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Mereo BioPharma Group NASDAQ:MREO$1.76 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.78 +0.01 (+0.85%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
